中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2011年
10期
1758-1760
,共3页
陈义初%邹明晖%周建良%董念国%史嘉玮
陳義初%鄒明暉%週建良%董唸國%史嘉瑋
진의초%추명휘%주건량%동념국%사가위
基质金属蛋白酶-2%聚乙二醇%组织工程%心脏瓣膜
基質金屬蛋白酶-2%聚乙二醇%組織工程%心髒瓣膜
기질금속단백매-2%취을이순%조직공정%심장판막
Matrix metalloproteinases-2%Polyethylene glycol%Tissue engineering%Heart valves
目的 采用相对分子质量20000 Da分枝状聚乙二醇(four-armed PEG-Ac)和基质金属蛋白酶-2(MMP-2)敏感型底物肽制备一种可降解复合水凝胶,并检测其性能.方法 以制备浓度为10% (w/v)的酶敏感型复合PEG水凝胶为实验A组,单纯PEG水凝胶为对照B组,比较两种水凝胶在37℃磷酸盐缓冲液(PBS)和血清的降解,并检测细胞毒性.在制胶过程中包埋转化生长因子(TGF-β1),观察两组水凝胶对TGF-β1的缓释效果.结果 PBS中A、B两组4周累计降解率分别为78.36%、76.28%,两者差异无统计学意义(P>0.05);分别添加正常人体血清,A组4周累计降解率为88.35%,降解速度加快,B组则变化不明显.噻唑蓝(MTT)比色法检测复合PEG水凝胶无细胞毒性.A、B两组水凝胶TGF-β17 d累计释放率分别为50.63%、44.36%,两者差异无统计学意义(P>0.05),分别添加MMP-2后,A组对TGF-β1的释放速度明显加快.结论 MMP-2敏感型PEG水凝胶结构稳定,对细胞无毒性,包埋TGF-β1有良好的控释效果,有望应用于新型组织工程心脏瓣膜支架材料的研制.
目的 採用相對分子質量20000 Da分枝狀聚乙二醇(four-armed PEG-Ac)和基質金屬蛋白酶-2(MMP-2)敏感型底物肽製備一種可降解複閤水凝膠,併檢測其性能.方法 以製備濃度為10% (w/v)的酶敏感型複閤PEG水凝膠為實驗A組,單純PEG水凝膠為對照B組,比較兩種水凝膠在37℃燐痠鹽緩遲液(PBS)和血清的降解,併檢測細胞毒性.在製膠過程中包埋轉化生長因子(TGF-β1),觀察兩組水凝膠對TGF-β1的緩釋效果.結果 PBS中A、B兩組4週纍計降解率分彆為78.36%、76.28%,兩者差異無統計學意義(P>0.05);分彆添加正常人體血清,A組4週纍計降解率為88.35%,降解速度加快,B組則變化不明顯.噻唑藍(MTT)比色法檢測複閤PEG水凝膠無細胞毒性.A、B兩組水凝膠TGF-β17 d纍計釋放率分彆為50.63%、44.36%,兩者差異無統計學意義(P>0.05),分彆添加MMP-2後,A組對TGF-β1的釋放速度明顯加快.結論 MMP-2敏感型PEG水凝膠結構穩定,對細胞無毒性,包埋TGF-β1有良好的控釋效果,有望應用于新型組織工程心髒瓣膜支架材料的研製.
목적 채용상대분자질량20000 Da분지상취을이순(four-armed PEG-Ac)화기질금속단백매-2(MMP-2)민감형저물태제비일충가강해복합수응효,병검측기성능.방법 이제비농도위10% (w/v)적매민감형복합PEG수응효위실험A조,단순PEG수응효위대조B조,비교량충수응효재37℃린산염완충액(PBS)화혈청적강해,병검측세포독성.재제효과정중포매전화생장인자(TGF-β1),관찰량조수응효대TGF-β1적완석효과.결과 PBS중A、B량조4주루계강해솔분별위78.36%、76.28%,량자차이무통계학의의(P>0.05);분별첨가정상인체혈청,A조4주루계강해솔위88.35%,강해속도가쾌,B조칙변화불명현.새서람(MTT)비색법검측복합PEG수응효무세포독성.A、B량조수응효TGF-β17 d루계석방솔분별위50.63%、44.36%,량자차이무통계학의의(P>0.05),분별첨가MMP-2후,A조대TGF-β1적석방속도명현가쾌.결론 MMP-2민감형PEG수응효결구은정,대세포무독성,포매TGF-β1유량호적공석효과,유망응용우신형조직공정심장판막지가재료적연제.
Objective To construct a biodegradable compound gel by four-armed polyethylene glycols (PEG) and matrix metalloproteinases-2 (MMP-2) sensitive substrate peptide,and investigate its properties.Methods Trials were randomly designed into two groups:MMP-2 enzymatically degradable PEG hydrogel (group A) and simple PEG hydrogel (group B).Degradation in different media was analyzed and the cell toxicity was observed.Transforming growth factor (TGF)-β1 was embedded into hydrogel during production process and its release rate was calculated.Results Compound gel had excellent stability.The degradation rate in phosphate buffer solution for four weeks was 78.36% and 76.28% in groups A and B respectively and had no significant difference between two groups (P > 0.05 ).After addition of the normal human serum,the degradation rate of group A reached 88.35%,and that of group B had no significant change.No cell toxicity of composite hydrogel was detected by methyl thiazol tetrazolium (MTT)test.TGF-β1 accumulative release rate at 7th day was 50.63% and 44.36% in groups A and B respectively ( P > 0.05).After addition of MMP-2,TGF-β1 release rate of group A was obviously increased.Conclusion This MMP-2 enzymatically degradable PEG hydrogel has stable structure and no cell toxicity,and can effectively control the release of TGF-β1.It is a potential material to fabricate new hybrid scaffold for tissue engineering of heart valves